TC BioPharm (Holdings) plc Warrants
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat … Read more
TC BioPharm (Holdings) plc Warrants (TCBPW) - Net Assets
Latest net assets as of September 2024: $2.00 Million USD
Based on the latest financial reports, TC BioPharm (Holdings) plc Warrants (TCBPW) has net assets worth $2.00 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.87 Million) and total liabilities ($4.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.00 Million |
| % of Total Assets | 29.17% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
TC BioPharm (Holdings) plc Warrants - Net Assets Trend (2019–2023)
This chart illustrates how TC BioPharm (Holdings) plc Warrants's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TC BioPharm (Holdings) plc Warrants (2019–2023)
The table below shows the annual net assets of TC BioPharm (Holdings) plc Warrants from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $2.69 Million | +710.60% |
| 2022-12-31 | $331.26K | +102.00% |
| 2021-12-31 | $-16.56 Million | -394.73% |
| 2020-12-31 | $-3.35 Million | -31.80% |
| 2019-12-31 | $-2.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TC BioPharm (Holdings) plc Warrants's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2342113500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.06K | 0.08% |
| Other Components | $41.52 Million | 1546.25% |
| Total Equity | $2.69 Million | 100.00% |
TC BioPharm (Holdings) plc Warrants Competitors by Market Cap
The table below lists competitors of TC BioPharm (Holdings) plc Warrants ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ODINWELL AB
F:0AF
|
$594.35K |
|
LSEB Creative Corp.
OTCQB:LSEB
|
$594.38K |
|
AKER -A-
BE:FKM
|
$594.75K |
|
GDO
F:GDO
|
$594.94K |
|
AMADEUS IT HOLD -A-
BE:AI3A
|
$592.75K |
|
Stone Gold Inc.
PINK:STGDF
|
$592.37K |
|
ARCHER-DANIELS MID.
MU:ADM
|
$592.26K |
|
Bravo Multinational Inc
PINK:BRVO
|
$591.36K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TC BioPharm (Holdings) plc Warrants's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 331,265 to 2,685,230, a change of 2,353,965 (710.6%).
- Net loss of 5,906,953 reduced equity.
- New share issuances of 4,186,862 increased equity.
- Other comprehensive income decreased equity by 16,710,757.
- Other factors increased equity by 20,784,813.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.91 Million | -219.98% |
| Share Issuances | $4.19 Million | +155.92% |
| Other Comprehensive Income | $-16.71 Million | -622.32% |
| Other Changes | $20.78 Million | +774.04% |
| Total Change | $- | 710.60% |
Book Value vs Market Value Analysis
This analysis compares TC BioPharm (Holdings) plc Warrants's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.28x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-141.72 | $0.01 | x |
| 2020-12-31 | $-0.30 | $0.01 | x |
| 2021-12-31 | $-2.12 | $0.01 | x |
| 2022-12-31 | $0.02 | $0.01 | x |
| 2023-12-31 | $0.02 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TC BioPharm (Holdings) plc Warrants utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -219.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.33x
- Recent ROE (-219.98%) is below the historical average (-123.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -177.07% | 0.34x | 0.00x | $-5.81 Million |
| 2020 | 0.00% | -275.84% | 0.27x | 0.00x | $-5.12 Million |
| 2021 | 0.00% | -686.12% | 0.25x | 0.00x | $-11.92 Million |
| 2022 | -396.54% | -34.17% | 0.34x | 34.09x | $-1.35 Million |
| 2023 | -219.98% | 0.00% | 0.00x | 3.33x | $-6.18 Million |
Industry Comparison
This section compares TC BioPharm (Holdings) plc Warrants's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TC BioPharm (Holdings) plc Warrants (TCBPW) | $2.00 Million | 0.00% | 2.43x | $593.22K |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |